The Alliance for Safe Biologic Medicines joined with the Virginia Biotechnology Association at an event to expore with patients, advocates, physicians and other healthcare providers the importance of maintaining patient safety as the U.S. FDA’s top priority while it works to establish a pathway for approval for biosimilar products.

Event Date and Time:
Wednesday, September 28, 2011 from 12:00pm – 2:00pm

Event Location:
Virginia Biotechnology Research Park, 800 E. Leigh St, Richmond, VA 23219.

Panelists Included:

  • Andrew Spiegel, Colon Cancer Alliance
  • Mark Herzog, Executive Director of VA Bio
  • Dr. Harry Gewanter, M.D., FAAP, FACR, Pediatric Rheumatologist.
  • Kim Greco, Amgen